Skip to main content

Table 1 Characteristics of study cohort at baseline (n = 32)

From: Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis

Characteristic n (%) unless indicated otherwise
Age in years, median (range) 63 (37–86)
Sex
 Male 23 (72%)
 Female 9 (28%)
BMI, median (range) 26 (20–38)
Primary site
 Colon 23 (72%)
 Rectum 9 (28%)
Definitive treatment to primary tumour 26 (81%)
Hepatic tumour burdena, median (range) 9 (1–46)
Hepatic tumour burdena > 25% 4 (13%)
Extrahepatic metastasesb 23 (72%)
Location of extrahepatic metastases  
 Lungs alone 13
 Lung and lymph nodes 2
 Lymph nodes alone 5
 Other 3
Prior therapies
 Lines of chemotherapy
 1
9 (28%)
 2 22 (69%)
 Anti-VEGF/EGFR mAb 28 (88%)
 Hepatic resection 11 (34%)
 RFA/SBRTc to liver 2 (6%)
 Isolated liver oxaliplatin 1 (3%)
 Radiotherapy to extrahepatic sites 6 (19%)
RAS mutation statusd
 Wild type 14 (44%)
 Mutant 10 (31%)
 Unknown 8 (25%)
Treatment to both liver lobes 19 (59%)
Prescribed amount of 90Y for treatment in GBq, median (range)e 1.68 (0.42–2.08)
Time to follow-up FDG PET/CTe in days, median (range) 56 (38–80)
  1. aAs measured by the MeVis® radiological service (MeVis Medical Solutions AG, Bremen, Germany), based on contrast enhanced CT performed at the time of baseline FDG PET/CT
  2. bDetected on FDG PET/CT
  3. cRFA, Radiofrequency ablation; SBRT, stereotactic body radiation therapy
  4. dKRAS/NRAS where tested
  5. eFrom sub-cohort of 22 patients with analysable lesion data only